Chidamide in Combination With Abemaciclib and Fulvestrant in Breast Cancer Patients Previously Treated With Palbociclib
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of chidamide in combination with abemaciclib and
fulvestrant in locally advanced/metastatic HR+/HER2- breast cancer who had failed prior
Palbociclib therapy